These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36111688)

  • 1. Visceral leishmaniasis elimination in India: progress and the road ahead.
    Singh OP; Sundar S
    Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1381-1388. PubMed ID: 36111688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence.
    Sundar S; Singh OP; Chakravarty J
    Expert Rev Anti Infect Ther; 2018 Nov; 16(11):805-812. PubMed ID: 30289007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased
    Cloots K; Marino P; Burza S; Gill N; Boelaert M; Hasker E
    Front Cell Infect Microbiol; 2021; 11():604117. PubMed ID: 33777831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmission Dynamics of Visceral Leishmaniasis in the Indian Subcontinent - A Systematic Literature Review.
    Hirve S; Boelaert M; Matlashewski G; Mondal D; Arana B; Kroeger A; Olliaro P
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004896. PubMed ID: 27490264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of eliminating visceral leishmaniasis from the Indian subcontinent: explorations with a set of deterministic age-structured transmission models.
    Le Rutte EA; Coffeng LE; Bontje DM; Hasker EC; Postigo JA; Argaw D; Boelaert MC; De Vlas SJ
    Parasit Vectors; 2016 Jan; 9():24. PubMed ID: 26787302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of visceral leishmaniasis elimination program in India: a picture imperfect.
    Gurunath U; Joshi R; Agrawal A; Shah V
    Expert Rev Anti Infect Ther; 2014 Aug; 12(8):929-35. PubMed ID: 24930676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the transmission dynamics of Leishmania donovani to provide robust evidence for interventions to eliminate visceral leishmaniasis in Bihar, India.
    Cameron MM; Acosta-Serrano A; Bern C; Boelaert M; den Boer M; Burza S; Chapman LA; Chaskopoulou A; Coleman M; Courtenay O; Croft S; Das P; Dilger E; Foster G; Garlapati R; Haines L; Harris A; Hemingway J; Hollingsworth TD; Jervis S; Medley G; Miles M; Paine M; Picado A; Poché R; Ready P; Rogers M; Rowland M; Sundar S; de Vlas SJ; Weetman D
    Parasit Vectors; 2016 Jan; 9():25. PubMed ID: 26812963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved kala-azar case management through implementation of health facility-based sentinel sites surveillance system in Bihar, India.
    Das VNR; Siddiqui NA; Bhunia GS; Pandey K; Sinha SK; Ansari MZ; Topno RK; Lal CS; Ranjan A; Singh VP; Das P
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009598. PubMed ID: 34428232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential impact of human visceral leishmaniasis vaccines on population incidence.
    Le Rutte EA; Coffeng LE; Malvolti S; Kaye PM; de Vlas SJ
    PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008468. PubMed ID: 32614857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health.
    Hirve S; Kroeger A; Matlashewski G; Mondal D; Banjara MR; Das P; Be-Nazir A; Arana B; Olliaro P
    PLoS Negl Trop Dis; 2017 Oct; 11(10):e0005889. PubMed ID: 29023446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inferring transmission trees to guide targeting of interventions against visceral leishmaniasis and post-kala-azar dermal leishmaniasis.
    Chapman LAC; Spencer SEF; Pollington TM; Jewell CP; Mondal D; Alvar J; Hollingsworth TD; Cameron MM; Bern C; Medley GF
    Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25742-25750. PubMed ID: 32973088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy.
    Mondal D; Singh SP; Kumar N; Joshi A; Sundar S; Das P; Siddhivinayak H; Kroeger A; Boelaert M
    PLoS Negl Trop Dis; 2009; 3(1):e355. PubMed ID: 19159009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
    Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
    PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of visceral leishmaniasis on the Indian subcontinent.
    Singh OP; Hasker E; Boelaert M; Sundar S
    Lancet Infect Dis; 2016 Dec; 16(12):e304-e309. PubMed ID: 27692643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
    Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
    Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India.
    Das VN; Pandey RN; Siddiqui NA; Chapman LA; Kumar V; Pandey K; Matlashewski G; Das P
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005196. PubMed ID: 27974858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective.
    Singh OP; Singh B; Chakravarty J; Sundar S
    Infect Dis Poverty; 2016 Mar; 5():19. PubMed ID: 26951132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Policy Recommendations From Transmission Modeling for the Elimination of Visceral Leishmaniasis in the Indian Subcontinent.
    Le Rutte EA; Chapman LAC; Coffeng LE; Ruiz-Postigo JA; Olliaro PL; Adams ER; Hasker EC; Boelaert MC; Hollingsworth TD; Medley GF; de Vlas SJ
    Clin Infect Dis; 2018 Jun; 66(suppl_4):S301-S308. PubMed ID: 29860292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
    Goyal V; Das VNR; Singh SN; Singh RS; Pandey K; Verma N; Hightower A; Rijal S; Das P; Alvar J; Bern C; Alves F
    PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008429. PubMed ID: 32687498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.